Philip Morris International Inc.

▲ Bull Case

• ◆Zyn becomes category-defining US franchise from 794M cans FY2025 to ~2.0B by FY2030 (+22% CAGR). At $2.50–3.00/can ASP, US Zyn revenue reaches $5–6B by 2030. FDA MRTP approval enables +5pp acceleration. SFP segment supports $80–120B equity value at consumer-growth multiples.
• ◆IQOS US becomes third leg of SFP growth via FDA-authorized commercial launch in 2026. Japan's 25%+ IQOS penetration precedent; even 5% US penetration = 1.5M users → $1B+ incremental revenue, $7–8/share equity value. Not modeled in consensus.
• ◆ESG reclassification + buyback resumption compounds re-rate. SFP >60% by FY2029–2030 enables transition tobacco → consumer staples/health, unlocking $50–100B institutional demand. $13–25B FY2028–2030 cumulative buybacks drive EPS CAGR from 9–11% to 11–14%. Bull fair value $260–310.

▼ Bear Case

• ◆FDA adverse Zyn ruling (strength cap <6mg, flavor restrictions, MRTP denial) + Altria On! PLUS competition compress US franchise. Zyn share 66–70% → 50–55% within 24 months; growth slows 37% → 12%. Zyn equity value collapses $60–80/sh.
• ◆Combustible volume decline accelerates beyond -2.5%/yr base. Plain packaging spread, illicit trade acceleration, cessation programs → -4–5%/yr volume. Pricing +5%/yr cannot offset; $23.6B combustibles base contracts. SFP growth cannot fully compensate.
• ◆Leverage trap constrains capital allocation. $44B net debt + $7.5–10B/yr dividend = zero flexibility. EPS shortfall forces dividend vs. balance-sheet tradeoff. Deleveraging slips past 2027 → buybacks delay → EPS CAGR falls 12.4% → 9–10%. Bear fair value $115–150.

“Central tension: 'Is PMI a smoke-free transformation success story priced as tobacco, OR an expensive Swedish Match re-rating that overshot?' Bull thesis: PMI priced as tobacco (22x P/E vs. KO/PG 24–25x) despite becoming consumer health company. Market applies structural discount ignoring SFP optionality, IQOS US multi-billion option, ESG reclassification at >66% SFP, buyback resumption FY2027–2028. PM is KO-growth at MO-multiples = 12–14% EPS CAGR. Bear thesis: Consensus accurately weights regulatory/competitive/macro risks. Path more vulnerable: FDA uncertainty, On! competition, EU TPD3, IQOS access challenges, leverage constraints. ESG exclusion may persist structurally. Terminal SFP value has no historical precedent. 22x multiple reflects most upside. Reality: Consensus PT $192 ≈ spot $188 (stock fairly priced). Alpha requires variant view.”

• ◆FDA Zyn MRTP final ruling (2026 within 12 months): +$10–15/sh if approved (HIGH); status quo if denied (minimal)
• ◆Q2 2026 earnings: Zyn >220M cans YoY confirms growth; SFP mix >43% signals acceleration
• ◆IQOS US milestones (Q2–Q4 2026): User count/revenue disclosure de-risks bull pillar
• ◆Net debt/EBITDA approaching 2.0x (YE2026–YE2027): Buyback resumption signals $3–6B/yr capacity
• ◆SFP mix crosses 50% (FY2027–FY2028): Symbolic threshold may trigger analyst reclassification and multiple expansion
• ◆Zyn US revenue ≥$3B annualized (FY2027–FY2028): Franchise validation; supports $5–6B FY2030 target
• ◆First buyback announcement (FY2027–FY2028): +$10–15/sh as EPS growth re-accelerates
• ◆EU TPD3 finalized (FY2026–FY2028): Binary outcome on flavor restrictions affects SFP path
• ◆ESG reclassification tobacco → consumer health (FY2029–FY2031): +$30–60/sh if institutional unlock materializes

• ◆FDA adverse Zyn MRTP/flavor/strength (LOW-MED probability, HIGH severity): Multi-pillar negative compresses growth 37% → 5–12%, invalidates thesis
• ◆Combustible volume accelerates >-5%/yr (LOW probability, MEDIUM severity): Exceeds pricing offset; consolidated revenue turns negative
• ◆Altria On! PLUS competition (MEDIUM probability, MEDIUM severity): Zyn share 66–70% → 50–55%; growth slows significantly
• ◆Leverage delays deleveraging past 2027 (LOW probability, MEDIUM severity): Buyback resumption delayed; EPS CAGR 12.4% → 9–10%
• ◆EU TPD3 flavor restrictions (MEDIUM probability, MEDIUM severity): Multi-year regulatory process affects SFP trajectory
• ◆IQOS US slower adoption (MEDIUM probability, MEDIUM severity): Bull pillar invalidated; SFP growth caps lower
• ◆Currency reversal / USD strength (MEDIUM probability, MEDIUM severity): $0.30–0.50/sh annual EPS sensitivity
• ◆ESG exclusion persists even at >66% SFP (HIGH probability, LOW-MED severity): Structural; institutional demand unlock may not materialize
• ◆Major Zyn youth access settlement (LOW probability, HIGH severity tail): $5–10B settlement + marketing restrictions
• ◆Dividend cut (VERY LOW probability, HIGH severity): Would signal FCF deterioration → -20% to -30% multiple compression
• ◆Pillar 2 global minimum tax (MEDIUM probability, LOW-MED severity): 22% → 24–25% rate → 1.5–2pp EPS CAGR drag